share_log

科濟藥業-B：股東週年大會適用之代表委任表格

CARSGEN-B: FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING

Hong Kong Stock Exchange ·  Apr 18 17:07
Summary by Futu AI
科济药业-B（股份代號：2171）將於2024年5月21日在上海舉行股東週年大會，屆時將審議包括核准2023年度財務報表及董事及核數師報告在內的多項議案。會議議程還包括重選執行董事李宗海博士和王華茂博士，非執行董事郭炳森先生，以及獨立非執行董事趙向可女士。此外，將討論授權董事會釐定董事薪酬、續聘安永會計師事務所為核數師及其薪酬，並授予董事發行及購回股份的一般授權。特別決議案包括批准章程修訂及採納經修訂及重述的組織章程大綱及細則。股東可委任代表出席大會並投票，代表委任表格需於2024年5月19日前送達香港中央證券登記有限公司。
科济药业-B（股份代號：2171）將於2024年5月21日在上海舉行股東週年大會，屆時將審議包括核准2023年度財務報表及董事及核數師報告在內的多項議案。會議議程還包括重選執行董事李宗海博士和王華茂博士，非執行董事郭炳森先生，以及獨立非執行董事趙向可女士。此外，將討論授權董事會釐定董事薪酬、續聘安永會計師事務所為核數師及其薪酬，並授予董事發行及購回股份的一般授權。特別決議案包括批准章程修訂及採納經修訂及重述的組織章程大綱及細則。股東可委任代表出席大會並投票，代表委任表格需於2024年5月19日前送達香港中央證券登記有限公司。
Kozai Pharmaceuticals-B (share code: 2171) will hold its Annual General Meeting in Shanghai on 21 May 2024, at which time a number of motions will be considered, including the approval of the 2023 financial statements and the reports of directors and auditors. The agenda also includes the re-election of Executive Directors Dr. Li Zonghai and Dr. Wang Huamao, Non-Executive Director Mr. Guo Pingsen, and Ms. Zhao, Independent Non-Executive Director. In addition, the discussion will be given to authorise the Board to determine the remuneration of directors, to renew EY as auditor and its remuneration, and to grant the directors general authority to issue and repurchase shares. The Special Resolution includes the approval of amendments to the Articles of Association and the adoption of the revised and revised Organization Statutes and Conditions. SHAREHOLDERS MAY APPOINT REPRESENTATIVES TO ATTEND THE GENERAL MEETING AND VOTE. THE FORM OF PROXY MUST BE SENT TO HONG KONG CENTRAL SECURITIES REGISTRY LIMITED BY 19 MAY 2024.
Kozai Pharmaceuticals-B (share code: 2171) will hold its Annual General Meeting in Shanghai on 21 May 2024, at which time a number of motions will be considered, including the approval of the 2023 financial statements and the reports of directors and auditors. The agenda also includes the re-election of Executive Directors Dr. Li Zonghai and Dr. Wang Huamao, Non-Executive Director Mr. Guo Pingsen, and Ms. Zhao, Independent Non-Executive Director. In addition, the discussion will be given to authorise the Board to determine the remuneration of directors, to renew EY as auditor and its remuneration, and to grant the directors general authority to issue and repurchase shares. The Special Resolution includes the approval of amendments to the Articles of Association and the adoption of the revised and revised Organization Statutes and Conditions. SHAREHOLDERS MAY APPOINT REPRESENTATIVES TO ATTEND THE GENERAL MEETING AND VOTE. THE FORM OF PROXY MUST BE SENT TO HONG KONG CENTRAL SECURITIES REGISTRY LIMITED BY 19 MAY 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.